Skip to main content
Premium Trial:

Request an Annual Quote

Labcorp OmniSeq Insight

Laboratory Corporation of America and OmniSeq have launched the OmniSeq Insight genomic and immune profiling test. The tissue-based test integrates next-generation sequencing technology to advance precision oncology, the firms said. OmniSeq Insight is a pan-cancer solid tumor test for genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression. Results are presented in an easy-to-read report that provides recommendations specific to the patient's results based on a proprietary database that includes information and guidelines from the National Comprehensive Cancer Network. The test is available to US clinicians exclusively through Labcorp and in Canada through Dynacare, a Labcorp company.

Labcorp and OmniSeq, a molecular diagnostics subsidiary of Roswell Park Cancer Institute, signed a distribution agreement in 2017 for OmniSeq's immune profiling and pan-cancer NGS tests, and they extended the deal in 2019.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.